Abstract
The efficacy and safety of combined metformin and rosiglitazone therapy in type 2 diabetes has been evaluated in an open-label, phase IV, prospective, multicentre study conducted in India over a period of 3 months in accordance with the principles of Good Clinical Practice and the Declaration of Helsinki. The superiority of the combination therapy in its effects on glycaemic parameters and lipid profile has been observed. A discussion of the same with brief review of literature has been presented here.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase IV
-
Multicenter Study
MeSH terms
-
Adult
-
Aged
-
Analysis of Variance
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Drug Therapy, Combination
-
Female
-
Humans
-
Hypoglycemic Agents / therapeutic use*
-
Male
-
Metformin / therapeutic use*
-
Middle Aged
-
Product Surveillance, Postmarketing
-
Prospective Studies
-
Rosiglitazone
-
Thiazoles / therapeutic use*
-
Thiazolidinediones*
-
Treatment Outcome
Substances
-
Hypoglycemic Agents
-
Thiazoles
-
Thiazolidinediones
-
Rosiglitazone
-
Metformin